导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.48% | 1940/4773 |
| 近一周 | 0.50% | 3255/5517 |
| 近一月 | -2.01% | 1093/5427 |
| 近一季 | -3.96% | 1784/5241 |
| 近半年 | -3.39% | 2814/4939 |
| 近一年 | 5.68% | 1854/4404 |
| 近两年 | 28.51% | 2374/2955 |
| 近三年 | 17.70% | 1573/2255 |
| 成立以来 | 57.24% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.21% 1604/4961 |
7.38% 2708/5312 |
- - |
- - |
| 2025 | 5.42% 3000/4813 |
-4.92% 3235/3635 |
1.00% 2502/4076 |
9.80% 3335/4524 |
-0.03% 2313/4813 |
| 2024 | 14.76% 1010/3463 |
4.80% 431/2808 |
2.01% 416/3014 |
7.99% 2779/3129 |
-0.60% 1473/3463 |
| 2023 | 1.70% 352/2656 |
12.22% 309/2280 |
-0.52% 387/2385 |
-4.67% 1195/2515 |
-4.43% 1029/2655 |
| 2022 | -14.98% 404/2207 |
-11.94% 558/1919 |
3.08% 1217/2016 |
-9.63% 291/2113 |
3.65% 662/2208 |
| 2021 | 15.95% 289/1822 |
-0.27% 346/1255 |
4.58% 869/1330 |
8.96% 150/1466 |
2.02% 724/1822 |
| 2020 | 14.36% 795/1250 |
-10.08% 750/1028 |
4.34% 910/1067 |
8.98% 687/1164 |
11.85% 516/1184 |
| 2019 | 5.68% 749/1092 |
12.53% 706/754 |
-7.04% 539/804 |
-1.43% 655/850 |
2.50% 863/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 博时央调ETF联接C VS. 长安沪深300非周期A(740101) |